Eylea, which is used to treat age-related macular degeneration, brought in roughly $9.4 billion in sales last year, down a ...

plus a reduced need for injections into the eye with current therapy Eylea. On the strength of the results, 4DMT is planning to start a phase 3 trial of the gene therapy by the end of the first ...

The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron ...

Regeneron (NASDAQ:REGN) won a permanent injunction that blocks drugmakers including, Mylan Pharmaceuticals/Biocon Biologics, ...

agreed to review their AVTO6 treatment for eye disorders. The treatment could compete with Regeneron Pharmaceuticals’ (REGN) Eylea, which is widely used to treat diseases such as neovascular ...

EYLEA HD and EYLEA are administered by injection into the eye. You should not use EYLEA HD or EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of ...

It returned to the market in the middle of last year – after updates to the implant and refill needle – as an alternative to AMD therapies that require regular injections into the eye ...

blockbuster eye disease therapy, Eylea. A biologic named AVT06, Teva (NYSE:TEVA), and Alvotech’s (NASDAQ:ALVO) biosimilar, is backed by positive data from a clinical trial for patients with ...

Regeneron Pharmaceuticals has built its success on a foundation of innovative drug development, with key products including Eylea for eye diseases and Dupixent for various inflammatory conditions.